Efficacy and safety of cemiplimab in cutaneous squamous cell carcinoma on chronic wounds: A French retrospective study
Background: Chronic wounds increase the risk of the development of cutaneous squamous cell carcinoma (SCC), often resulting in poor prognosis in part because of delayed diagnosis. Cemiplimab, an anti-PD-1 agent, is recommended as first-line treatment for metastatic or locally advanced SCC not eligib...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-12-01
|
| Series: | EJC Skin Cancer |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2772611824002611 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850061644591267840 |
|---|---|
| author | M. Antoszczak E. Maubec A.-B. Duval-Modeste A. Jannic C. Jacobzone-Leveque R. Lesbazeilles F. Skowron D. Solub J. Ancel L. Mortier M. Viguier |
| author_facet | M. Antoszczak E. Maubec A.-B. Duval-Modeste A. Jannic C. Jacobzone-Leveque R. Lesbazeilles F. Skowron D. Solub J. Ancel L. Mortier M. Viguier |
| author_sort | M. Antoszczak |
| collection | DOAJ |
| description | Background: Chronic wounds increase the risk of the development of cutaneous squamous cell carcinoma (SCC), often resulting in poor prognosis in part because of delayed diagnosis. Cemiplimab, an anti-PD-1 agent, is recommended as first-line treatment for metastatic or locally advanced SCC not eligible for curative surgery, chemotherapy or radiation. However, its efficacy in SCC originating from chronic wounds remains uncertain. Objective: This retrospective study assessed the efficacy and safety of cemiplimab in patients with SCC originating from chronic wounds. Methods: We included patients receiving cemiplimab for SCC on chronic wounds between August 2018 and January 2021. The primary endpoint was progression-free survival (PFS) determined by Kaplan-Meier analysis. Secondary endpoints included response rate and safety. Results: We included 17 patients, predominantly female (59 %), with median age 58 years (interquartile range 49–77). SCC typically originated from leg ulcers (47 %) and presented at locally advanced (41 %) or metastatic stage (41 %). With cemiplimab, often received as third-line therapy (41 %), the median PFS was 6.1 months (95 % confidence interval [CI], 2.97–7.70), with the best response rate 47 % and complete response rate 12 %. We found immune-related adverse events in 24 % of cases. Short PFS was associated with distant metastasis at treatment initiation. Conclusion: Despite response rates comparable to other SCC types, median PFS was low with cemiplimab treatment for SCC originating from chronic wounds, likely due to the aggressive nature and/or high frequency of altered performance status. Anti-PD-1 therapy remains a primary treatment option for inoperable cases. Further prospective studies are warranted to confirm these findings and optimize treatment strategies. |
| format | Article |
| id | doaj-art-ec4af130a98a4eefa6ac6c308d6216e4 |
| institution | DOAJ |
| issn | 2772-6118 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | EJC Skin Cancer |
| spelling | doaj-art-ec4af130a98a4eefa6ac6c308d6216e42025-08-20T02:50:09ZengElsevierEJC Skin Cancer2772-61182024-12-01210027310.1016/j.ejcskn.2024.100273Efficacy and safety of cemiplimab in cutaneous squamous cell carcinoma on chronic wounds: A French retrospective studyM. Antoszczak0E. Maubec1A.-B. Duval-Modeste2A. Jannic3C. Jacobzone-Leveque4R. Lesbazeilles5F. Skowron6D. Solub7J. Ancel8L. Mortier9M. Viguier10Dermatology Department, Robert-Debré Hospital, Reims-Champagne Ardenne University, EA7509 IRMAIC, Reims, FranceDermatology Department, Avicenne University Hospital, Assistance Publique–Hôpitaux de Paris (AP-HP), Sorbonne-Paris-Nord University, Bobigny, France; INSERM UMR1124, Paris Cité University, FranceDermatology Department, Charles-Nicolle Hospital, Rouen, FranceDermatology Department, Henri-Mondor Hospital, APHP, Créteil, FranceDermatology Department, Scorff Hospital, Lorient, FranceDermatology Department, Poitiers University Hospital, Poitiers, FranceDermatology Department, North Drome Hospital, Romans-Sur-Is, FranceDermatology Department, Louis Pasteur Hospital, Le Coudray, FranceUniversité de Reims Champagne-Ardenne, INSERM, P3Cell, UMR-S 1250, SFR CAP Santé, Reims, FranceDermatology Department, Lille University Hospital, Lille, France; INSERM UMR1189, Lille University, FranceDermatology Department, Robert-Debré Hospital, Reims-Champagne Ardenne University, EA7509 IRMAIC, Reims, France; Correspondence to: Department of Dermatology, Hôpital Robert-Debré, Avenue du Général Koenig, Reims Cedex 51092, France.Background: Chronic wounds increase the risk of the development of cutaneous squamous cell carcinoma (SCC), often resulting in poor prognosis in part because of delayed diagnosis. Cemiplimab, an anti-PD-1 agent, is recommended as first-line treatment for metastatic or locally advanced SCC not eligible for curative surgery, chemotherapy or radiation. However, its efficacy in SCC originating from chronic wounds remains uncertain. Objective: This retrospective study assessed the efficacy and safety of cemiplimab in patients with SCC originating from chronic wounds. Methods: We included patients receiving cemiplimab for SCC on chronic wounds between August 2018 and January 2021. The primary endpoint was progression-free survival (PFS) determined by Kaplan-Meier analysis. Secondary endpoints included response rate and safety. Results: We included 17 patients, predominantly female (59 %), with median age 58 years (interquartile range 49–77). SCC typically originated from leg ulcers (47 %) and presented at locally advanced (41 %) or metastatic stage (41 %). With cemiplimab, often received as third-line therapy (41 %), the median PFS was 6.1 months (95 % confidence interval [CI], 2.97–7.70), with the best response rate 47 % and complete response rate 12 %. We found immune-related adverse events in 24 % of cases. Short PFS was associated with distant metastasis at treatment initiation. Conclusion: Despite response rates comparable to other SCC types, median PFS was low with cemiplimab treatment for SCC originating from chronic wounds, likely due to the aggressive nature and/or high frequency of altered performance status. Anti-PD-1 therapy remains a primary treatment option for inoperable cases. Further prospective studies are warranted to confirm these findings and optimize treatment strategies.http://www.sciencedirect.com/science/article/pii/S2772611824002611Squamous cell carcinomaImmunotherapyWounds and injuriesLeg ulcer |
| spellingShingle | M. Antoszczak E. Maubec A.-B. Duval-Modeste A. Jannic C. Jacobzone-Leveque R. Lesbazeilles F. Skowron D. Solub J. Ancel L. Mortier M. Viguier Efficacy and safety of cemiplimab in cutaneous squamous cell carcinoma on chronic wounds: A French retrospective study EJC Skin Cancer Squamous cell carcinoma Immunotherapy Wounds and injuries Leg ulcer |
| title | Efficacy and safety of cemiplimab in cutaneous squamous cell carcinoma on chronic wounds: A French retrospective study |
| title_full | Efficacy and safety of cemiplimab in cutaneous squamous cell carcinoma on chronic wounds: A French retrospective study |
| title_fullStr | Efficacy and safety of cemiplimab in cutaneous squamous cell carcinoma on chronic wounds: A French retrospective study |
| title_full_unstemmed | Efficacy and safety of cemiplimab in cutaneous squamous cell carcinoma on chronic wounds: A French retrospective study |
| title_short | Efficacy and safety of cemiplimab in cutaneous squamous cell carcinoma on chronic wounds: A French retrospective study |
| title_sort | efficacy and safety of cemiplimab in cutaneous squamous cell carcinoma on chronic wounds a french retrospective study |
| topic | Squamous cell carcinoma Immunotherapy Wounds and injuries Leg ulcer |
| url | http://www.sciencedirect.com/science/article/pii/S2772611824002611 |
| work_keys_str_mv | AT mantoszczak efficacyandsafetyofcemiplimabincutaneoussquamouscellcarcinomaonchronicwoundsafrenchretrospectivestudy AT emaubec efficacyandsafetyofcemiplimabincutaneoussquamouscellcarcinomaonchronicwoundsafrenchretrospectivestudy AT abduvalmodeste efficacyandsafetyofcemiplimabincutaneoussquamouscellcarcinomaonchronicwoundsafrenchretrospectivestudy AT ajannic efficacyandsafetyofcemiplimabincutaneoussquamouscellcarcinomaonchronicwoundsafrenchretrospectivestudy AT cjacobzoneleveque efficacyandsafetyofcemiplimabincutaneoussquamouscellcarcinomaonchronicwoundsafrenchretrospectivestudy AT rlesbazeilles efficacyandsafetyofcemiplimabincutaneoussquamouscellcarcinomaonchronicwoundsafrenchretrospectivestudy AT fskowron efficacyandsafetyofcemiplimabincutaneoussquamouscellcarcinomaonchronicwoundsafrenchretrospectivestudy AT dsolub efficacyandsafetyofcemiplimabincutaneoussquamouscellcarcinomaonchronicwoundsafrenchretrospectivestudy AT jancel efficacyandsafetyofcemiplimabincutaneoussquamouscellcarcinomaonchronicwoundsafrenchretrospectivestudy AT lmortier efficacyandsafetyofcemiplimabincutaneoussquamouscellcarcinomaonchronicwoundsafrenchretrospectivestudy AT mviguier efficacyandsafetyofcemiplimabincutaneoussquamouscellcarcinomaonchronicwoundsafrenchretrospectivestudy |